Aldeyra Therapeutics Inc.
Organization details
- Legal name
- Aldeyra Therapeutics Inc.
- Former names
- Aldexa Therapeutics, Inc. Neuron Systems Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Lexington
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALDX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001341235
Board of directors
-
Ben Bronstein · DirectorSince 2023
-
Darlene M. Deptula-Hicks · DirectorSince 2026
-
Gary M. Phillips · DirectorSince 2023
-
Martin Joseph Joyce · DirectorSince 2023
-
Nancy Miller-Rich · DirectorSince 2023
-
Neal Walker · DirectorSince 2023
-
Richard Douglas · DirectorSince 2023
-
Todd C. Brady · Director · President and CEOSince 2023
-
William D. Clark · DirectorSince 2025
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.5%
Board connections
4 of this board's directors also sit on 5 other boards. 5 are in the same sector.
-
4D Molecular Therapeutics Inc. Same sectorvia Nancy Miller-Rich
-
Aclaris Therapeutics Inc. Same sectorvia Neal Walker
-
MaxCyte Inc. Same sectorvia Richard Douglas
-
Novavax Inc. Same sectorvia Richard Douglas
-
iBio Inc. Same sectorvia William D. Clark
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $658,000
- 5 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 11, 2026 | Richard Douglas Director | Open-market purchase | +200,000 | $0.64 | $128,900 |
| Nov 11, 2026 | Alfieri Michael Officer (Principal Financial Officer) | Open-market purchase | +10,000 | $0.65 | $6,500 |
| Jun 3, 2026 | Todd C. Brady Director, Officer (President and CEO) | Open-market purchase | +250,000 | $1.67 | $417,500 |
| Mar 19, 2026 | Richard Douglas Director | Open-market purchase | +70,000 | $1.40 | $98,000 |
| Mar 18, 2026 | Alfieri Michael Officer (Principal Financial Officer) | Open-market purchase | +5,000 | $1.42 | $7,100 |
| Aug 13, 2025 | Alfieri Michael Officer (Principal Financial Officer) | Open-market purchase | +2,500 | $5.30 | $13,250 |
| Aug 11, 2025 | Machatha Stephen Officer (Chief Development Officer) | Open-market sale | −22,073 | $5.15 | $113,676 |
| Apr 3, 2025 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% owner | Open-market sale | −3,400,000 | $1.42 | $4,828,000 |
| Aug 12, 2024 | Machatha Stephen Officer (Chief Development Officer) | Open-market sale | −16,041 | $4.74 | $76,034 |
| Aug 12, 2024 | Greenberg Bruce Officer (See Remarks) | Open-market sale | −10,834 | $4.74 | $51,353 |
| Apr 5, 2024 | Joseph Edelman 10% owner | Open-market purchase | +37,712 | $4.74 | $178,755 |
| Apr 4, 2024 | Joseph Edelman 10% owner | Open-market purchase | +140,281 | $4.67 | $655,112 |
| Apr 3, 2024 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% owner | Open-market purchase | +309,847 | $4.09 | $1,267,274 |
| Apr 2, 2024 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% owner | Open-market purchase | +186,051 | $3.44 | $640,015 |
| Apr 1, 2024 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% owner | Open-market purchase | +8,374 | $3.25 | $27,216 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Aldeyra Therapeutics Inc.
Who is the CEO of Aldeyra Therapeutics Inc.?
Todd C. Brady is Aldeyra Therapeutics Inc.'s President and CEO.
How many directors are on Aldeyra Therapeutics Inc.'s board?
Aldeyra Therapeutics Inc.'s board has 9 directors: Ben Bronstein, Darlene M. Deptula-Hicks, Gary M. Phillips, Martin Joseph Joyce, Nancy Miller-Rich, Neal Walker, Richard Douglas, Todd C. Brady and William D. Clark.
Are Aldeyra Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Aldeyra Therapeutics Inc. insiders bought $658,000 of shares in 5 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="aldeyra-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.